Mouton,
I should have read your post before making my last post as I was wrong about some comments. You are right that LEO will be infusing for only 5 days as opposed to 4 days in the study, which surprises me that they wouldn't be monitoring and redosing later in an effort to maintain ATIII at more physiological levels. Second, there is no mention of prescreening for ATIII levels prior to administration. However, the paper in question tried to use extremely high doses of ATIII so it is unlikely that LEO will do the same. Still, I think these are points which should be clarified by someone calling IR of GTCB.
Nice work,
Vinnys
